Insider Selling: Kura Oncology (NASDAQ:KURA) COO Sells 3,668 Shares of Company Stock

29 Sep 2026, 23:08 by Tristan Rich · The Markets Daily

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) COO Kathleen Ford sold 3,668 shares of the company’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $39,431.00. Following the sale, the chief operating officer directly owned 142,986 shares of the company’s stock, valued at $1,537,099.50. The trade was a 2.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kathleen Ford also recently made the following trade(s):

On Monday, September 28th, Kathleen Ford sold 6,906 shares of Kura Oncology stock. The shares were sold at an average price of $10.50, for a total transaction of $72,513.00.

Kura Oncology Stock Performance

Shares of Kura Oncology stock traded up $0.20 on Tuesday, reaching $10.81. The stock had a trading volume of 1,890,260 shares, compared to its average volume of 1,673,937. The business’s 50-day moving average price is $11.22 and its two-hundred day moving average price is $10.15. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. Kura Oncology, Inc. has a fifty-two week low of $7.36 and a fifty-two week high of $13.90. The stock has a market cap of $961.66 million, a P/E ratio of -3.21 and a beta of 0.44.

Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. On average, sell-side analysts forecast that Kura Oncology, Inc. will post -3.25 EPS for the current year.

More Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.

Analysts Set New Price Targets

KURA has been the topic of a number of recent analyst reports. Wells Fargo & Company set a $24.00 price objective on Kura Oncology in a research note on Thursday, June 4th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Monday, August 24th. Morgan Stanley set a $24.00 price target on Kura Oncology in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Get Our Latest Report on KURA

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Tidal Investments LLC bought a new stake in shares of Kura Oncology in the second quarter valued at about $1,029,000. WINTON GROUP Ltd grew its position in Kura Oncology by 26.2% during the second quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock worth $143,000 after buying an additional 2,700 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in Kura Oncology during the second quarter valued at about $159,000. IFP Advisors Inc increased its stake in Kura Oncology by 136.5% during the second quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock valued at $28,000 after acquiring an additional 1,467 shares during the period. Finally, Allworth Financial LP raised its holdings in Kura Oncology by 148.4% in the 2nd quarter. Allworth Financial LP now owns 10,326 shares of the company’s stock valued at $113,000 after acquiring an additional 6,169 shares in the last quarter.

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.